Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protease nexin-1 (SERPINE2)
- Target
- SERPINE2
- Molecular classification
- Enzyme inhibitor (specifically, serine protease inhibitor), Secreted protein, Serpin superfamily (Serine protease inhibitor superfamily), Other (Extracellular matrix-associated protein)
01
Overview
Protease nexin-1 (PN-1, encoded by the SERPINE2 gene) is a secreted serine protease inhibitor of the serpin superfamily that inhibits thrombin, plasmin, tissue-type plasminogen activator, and urokinase-type plasminogen activator, acting as a critical regulator of hemostasis, fibrinolysis, and extracellular matrix remodeling. PN-1 is widely expressed in the brain (where it exerts neurotrophic and neuroprotective effects), vasculature, and various peripheral tissues. It is implicated in diverse physiological processes, including neuronal survival, angiogenesis inhibition, and tissue repair, and has pathogenic roles in cardiac fibrosis, cancer progression, and some pulmonary diseases.
- Other names
- Glia-derived nexinGDNPN-1PN1PI-7PNINexinPeptidase inhibitor 7Protease nexin ISerpin E2Glial-derived nexinGlial-derived neurite promoting factorGDNPF
02
Mechanism of action
Serine protease inhibition (forms irreversible complexes with target proteases, e.g., thrombin, plasmin, uPA, tPA), blocking proteolytic activity and thus affecting blood coagulation, fibrinolysis, and matrix remodeling
03
Biological functions
Inhibition of serine proteases (notably thrombin, plasmin, urokinase, tissue-type plasminogen activator)Regulation of extracellular matrix remodelingNeurotrophic activity/neuroprotection (promotes neurite outgrowth, inhibits neuronal cell death)Modulation of angiogenesis (antiangiogenic properties in retina)Regulation of cellular signaling (related to hemostasis, thrombolysis, and ECM)
04
Disease associations
Cardiovascular disease (cardiac fibrosis and remodeling)Cancer (e.g., vascular mimicry in breast cancer)Pulmonary disease (susceptibility gene for chronic obstructive pulmonary disease and emphysema)Neurodegenerative disease (related to neuroprotection in CNS and retina)
05
Safety considerations
Targeting SERPINE2 could potentially interfere with normal blood coagulation and fibrinolysis (risk of bleeding or excessive clotting)Modulation of extracellular matrix remodeling could impact tissue healing or fibrosis progression
06
Biomarkers
Increased SERPINE2 expression in cardiac fibrosis, certain cancers, and pulmonary diseases suggests potential biomarker roles in these conditions, but specific clinical biomarkers are not established in current literature
Beyond the preview
Go deeper on Protease nexin-1 (SERPINE2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protease nexin-1 (SERPINE2).